Results 31 to 40 of about 68,714 (218)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

Haematologica, 2018
Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib.
Mathias Schneeweiss, Barbara Peter, Siham Bibi, Gregor Eisenwort, Dubravka Smiljkovic, Katharina Blatt, Mohamad Jawhar, Daniela Berger, Gabriele Stefanzl, Susanne Herndlhofer, Georg Greiner, Gregor Hoermann, Emir Hadzijusufovic, Karoline V. Gleixner, Peter Bettelheim, Klaus Geissler, Wolfgang R. Sperr, Andreas Reiter, Michel Arock, Peter Valent   +19 more
doaj   +1 more source

Regulation of mast cell function and survival in health and disease [PDF]

, 2016
Mast cells are sentinels of danger but they are also the major effector cells in allergic disease causing the well-known allergic symptoms caused by their mediators such as histamine and prostaglandin D2 that are released upon activation. Mastocytosis is
Lyberg, Katarina
core   +1 more source

Diffuse large B cell lymphoma coexistence with systemic mastocytosis

Journal of Cancer Research and Practice, 2016
Systemic mastocytosis is a rare disease and characterized by excessive mast cell accumulation in one or multiple organs. One subtype of systemic mastocytosis is systemic mastocytosis-associated clonal hematological non-mast cell lineage disease (SM-AHMND)
Sheng-Hsuan Chien, Yao-Chung Liu, Ying-Chung Hong, Ching-Fen Yang, Chun-Yu Liu, Tzeon-Jye Chiou, Cheng-Hwai Tzeng, Jin-Hwang Liu, Jyh-Pyng Gau   +8 more
doaj   +1 more source

Mast Cell Sarcoma of the Retroperitoneum With Concurrent Systemic Mastocytosis and an Undisclosed Associated Hematologic Neoplasm: A Case Report

Clinical Pathology, 2022
Mastocytosis is a rare disorder affecting both children and adults by gathering of functionally defective mast cells in the body’s tissues. The World Health Organization (WHO) classified mastocytosis into cutaneous mastocytosis, systemic mastocytosis (SM)
Ing Chen, Jia-Bin Liao, Jung-Chia Lin, Pin-Pen Hsieh, Ming-Yun Hsieh   +4 more
doaj   +1 more source

Routine abdominal ultrasonography has limited value in the care for patients with indolent systemic mastocytosis [PDF]

, 2017
Objectives: Systemic mastocytosis (SM) is a myeloproliferative disease characterized by the accumulation of aberrant mast cells. Since advanced subtypes of SM can lead to organ dysfunction and shortened survival, timely recognition of progressive disease
Daele, P.L.A. (Paul) van, de Mol, C.L., Gerth van Wijk, R. (Roy), Hagen, P.M. (Martin) van, Hermans, M.A.W. (Maud A.W.)   +4 more
core   +2 more sources

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder [PDF]

, 2015
Although more than 90% systemic mastocytosis (SM) patients express gain of function mutations in the KIT receptor, recent next generation sequencing has revealed the presence of several additional genetic and epigenetic mutations in a subset of these ...
Chatterjee, Anindya, Ghosh, Joydeep, Kapur, Reuben   +2 more
core   +2 more sources

Solitary mastocytoma presenting in an adult: report and literature review of adult-onset solitary cutaneous mastocytoma with recommendations for evaluation and treatment

Dermatology Practical & Conceptual, 2016
Background: Mastocytosis is either cutaneous (with skin-limited proliferation of mast cells) or systemic (with mast cells in extracutaneous sites). The onset of solitary mastocytoma in an adult is rare.
Philip R. Cohen
doaj   +1 more source

International consensus on (ICON) anaphylaxis [PDF]

, 2014
ICON: Anaphylaxis provides a unique perspective on the principal evidence-based anaphylaxis guidelines developed and published independently from 2010 through 2014 by four allergy/immunology organizations.
Alvarez-Twose, Antonella Muraro, Arga, Armstrong, Arroabarren, Aziz Sheikh, Barnett, Bauer, Belhocine, Ben-Shoshan, Bilo, Bonadonna, Boyce, Boyle, Brockow, Brouwers, Brown, Brown, Brown, Brown, Caffarelli, Camargo, Campbell, Campbell, Campbell, Cetinkaya, Chad, Chiang, Choo, Cox, Cummings, Dana V. Wallace, de Silva, Dhami, Duke, Edwards, Ellis, Enarson, F. Estelle R. Simons, Field, Fineman, Fleischer, Gibbison, Gibbs, Golden, Gonzalez-Perez, Grabenhenrich, Graham Roberts, Harduar-Morano, Heinzerling, Hoffer, Iribarren, Jang, Jones, Kalesnikoff, Kelleher, Khodoun, Kim, Kim, Lafuente, Landsman-Blumberg, Ledit R.F. Ardusso, Lee, Li, Lieberman, Liew, Liew, Liu, Lotvall, Ludman, Lynette P. Shek, M Beatrice Bilò, Margitta Worm, Mario Sanchez-Borges, Mertes, Minciullo, Motohiro Ebisawa, Muller, Muraro, Ng, Nicklas, Noimark, Nurmatov, Panesar, Park, Perel, Phil Lieberman, Raimer, Ralston, Renaudin, Ribeiro-Vaz, Richard F. Lockey, Rudders, Rudders, Rueff, Rueff, Sala-Cunill, Sampson, Sampson, Sanchez-Borges, Sanchez-Borges, Schneider, Sheikh, Sheikh, Shemesh, Shen, Sicherer, Sicherer, Simons, Simons, Simons, Simons, Simons, Simons, Simons, Simons, Simons, Sole, Stoevesandt, Strohmeier, Takahashi, Tanno, Techapornroong, Tejedor Alonso, Thong, Topal, Triggiani, Vadas, Vadas, Vale, Valent, Vereda, Victoria Cardona, Wolbing, Wood, Wood, Worm, Yehia M. El-Gamal   +137 more
core   +3 more sources

Klinikai tapasztalataink cutan mastocytosisban. [PDF]

, 2013
Introduction: Mastocytosis is a clonal mast cell proliferative disease, devided into cutaneous and systemic forms. The characteristic symptoms are caused by neoplastic mast cell infiltrations in different organs and/or the release of mediators.
Csomor, Judit, Hidvégi, Bernadett, Hársing, Judit, Kovalszky, Ilona, Kárpáti, Sarolta, Marschalkó, Márta, Mihalik, Noémi, Várkonyi, Judit   +7 more
core   +1 more source

An intriguing coexistence of cutaneous and systemic mastocytosis with atypical chronic myeloid leukemia: An associated hematologic neoplasm (SM-AHN)

Journal of Applied Hematology, 2021
Systemic mastocytosis (SM) characterized by focal or diffuse infiltrates of neoplastic mast cells can range from indolent cutaneous disease to aggressive systemic disease.
B R Rajalakshmi, Vijaya Basavaraj
doaj   +1 more source